Abstract 174P
Background
Vitamin D deficiency is associated with various types of cancer, including breast cancer (BC), therefore interest has been increasing in recent years to address the role of vitamin D supplementation in cancer. Thus, we aimed to clarify whether successful vitamin D supplementation could predict improved survival in BC survivors after completion of adjuvant treatment.
Methods
BC survivors who completed primary treatment for early stage BC were enrolled in the study. Patients’ clinical features were recorded as follow: age, menopausal status, tumor features, including luminal types, pathological subtypes, and stage. Initial vitamin D levels of the patients and the median value of vitamin D after supplementation for patients who have insufficient vitamin D were noted. The patients were evaluated under four groups according to the vitamin D value at baseline and during follow-up. Log-rank statistics were used to compare survival distributions among groups.
Results
In total, 635 patients were analyzed in this retrospective study. 123 patients (19.4%) had sufficient vitamin D levels at baseline (group 1). 512 patients (80.6%) had insufficient vitamin D levels; 225 patients (35.4%) reached sufficient vitamin D values after supplementation (group 3), 287 patients (45.2%) had remained in insufficient levels at follow up (group 2). While stage and vitamin D groups were independently prognostic for disease free survival (DFS), pre-perimenopausal status, triple-negative disease and vitamin D groups (for group 2) were independent prognostic for overall survival (OS).
Conclusions
Vitamin D suplementation provide better DFS and OS for patients who have initially insufficient vitamin D. Even vitamin D supplementation, insufficient levels of vitamin D at follow up is still poor prognostic.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Elif Isbilen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.